- Home
- GILD vs IBN Comparison
GILD vs IBN Comparison
Compare GILD & IBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- IBN
- Stock Information
- Founded
- GILD 1987
- IBN 1955
- Country
- GILD United States
- IBN India
- Employees
- GILD N/A
- IBN N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- IBN Commercial Banks
- Sector
- GILD Health Care
- IBN Finance
- Exchange
- GILD Nasdaq
- IBN Nasdaq
- Market Cap
- GILD 129.9B
- IBN 121.2B
- IPO Year
- GILD 1992
- IBN 1999
- Fundamental
- Price
- GILD $109.11
- IBN $32.77
- Analyst Decision
- GILD Buy
- IBN
- Analyst Count
- GILD 25
- IBN 0
- Target Price
- GILD $110.17
- IBN N/A
- AVG Volume (30 Days)
- GILD 7.8M
- IBN 4.0M
- Earning Date
- GILD 08-07-2025
- IBN 07-28-2025
- Dividend Yield
- GILD 2.93%
- IBN 0.73%
- EPS Growth
- GILD 1118.07
- IBN 14.82
- EPS
- GILD 4.73
- IBN 0.83
- Revenue
- GILD $28,735,000,000.00
- IBN $23,482,887,936.00
- Revenue This Year
- GILD $1.55
- IBN N/A
- Revenue Next Year
- GILD $3.69
- IBN $14.57
- P/E Ratio
- GILD $22.83
- IBN $19.42
- Revenue Growth
- GILD 4.68
- IBN 40.52
- 52 Week Low
- GILD $62.69
- IBN $26.59
- 52 Week High
- GILD $119.96
- IBN $34.50
- Technical
- Relative Strength Index (RSI)
- GILD 49.92
- IBN 43.36
- Support Level
- GILD $107.19
- IBN $32.59
- Resistance Level
- GILD $111.78
- IBN $33.50
- Average True Range (ATR)
- GILD 2.77
- IBN 0.25
- MACD
- GILD -0.44
- IBN -0.16
- Stochastic Oscillator
- GILD 33.91
- IBN 20.54
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About IBN ICICI Bank Limited
ICICI Bank Ltd provides banking services. The company's operating segments include Retail Banking; Wholesale Banking; Treasury, Life insurance, Other Banking Business, and Others. The company generates maximum revenue from the Retail Banking segment which includes exposures of the Bank, which satisfy the four qualifying criteria of a regulatory retail portfolio as stipulated by RBI guidelines on the Basel III framework as well as includes income from credit cards, debit cards, third party product distribution, and the associated costs. Geographical segments include Domestic operations and Foreign operations. The company generates the majority of its revenue from the domestic operations.